洞察市场格局
解锁药品研发情报

免费客服电话

18983288589
试用企业版

【ChiCTR2100042375】Evaluation of Biomarkers for Prediction of Morbidity and Mortality in COVID-19 at a Tertiary Care Center in Pakistan

基本信息
登记号

ChiCTR2100042375

试验状态

结束

药物名称

/

药物类型

/

规范名称

/

首次公示信息日的期

2021-01-21

临床申请受理号

/

靶点

/

适应症

新型冠状病毒肺炎(COVID-19)

试验通俗题目

Evaluation of Biomarkers for Prediction of Morbidity and Mortality in COVID-19 at a Tertiary Care Center in Pakistan

试验专业题目

Evaluation of Biomarkers for Prediction of Morbidity and Mortality in COVID-19 at a Tertiary Care Center in Pakistan

申办单位信息
申请人联系人
申请人名称
联系人邮箱
联系人邮编

74800

联系人通讯地址
临床试验信息
试验目的

To evaluate the association of Serum Procalcitonin and other biochemical markers including ferritin, CRP, IL-6 with severity in Coronavirus disease 2019 (COVID-19), hospitalized patients and to test the hypothesis that they are an independent predictor of mortality.

试验分类
试验类型

析因分组(即根据危险因素或暴露因素分组)

试验分期

探索性研究/预试验

随机化

Owing to the retrospective data analysis, biochemical marker levels were obtained within 48 hours of admission for all in patients as routine care protocol of COVID-19.

盲法

N/A

试验项目经费来源

No

试验范围

/

目标入组人数

86;71

实际入组人数

/

第一例入组时间

2020-03-01

试验终止时间

2020-08-10

是否属于一致性

/

入选标准

both genders and aged 18 years and older groups with SARS-CoV-2 positive on a reverse-transcriptase polymerase chain reaction (PCR) test and received treatment at our center;

排除标准

1) biochemical work up on admission not undertaken; 2) known thalassemic cases.;

研究者信息
研究负责人姓名
试验机构

No

研究负责人电话
研究负责人邮箱
研究负责人邮编

74800

联系人通讯地址
<END>

No的其他临床试验

最新临床资讯

对摩熵医药数据库感兴趣,可以免费体验产品

同适应症药物临床试验